These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 10575561)

  • 1. Clinical outcome of chronic hepatitis C in patients treated with interferon: comparison between responders and non-responders.
    Morisco F; Marmo R; Iasevoli P; Sessa G; Tuccillo C; Del Vecchio Blanco C; Caporaso N
    Ital J Gastroenterol Hepatol; 1999; 31(6):454-8. PubMed ID: 10575561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of hepatic HCV RNA in patients with chronic hepatitis C demonstrating long-term sustained response to interferon-alpha therapy.
    Larghi A; Tagger A; Crosignani A; Ribero ML; Bruno S; Portera G; Battezzati PM; Maggioni M; Fasola M; Zuin M; Podda M
    J Med Virol; 1998 May; 55(1):7-11. PubMed ID: 9580879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up study of sustained biochemical responders with interferon therapy.
    Shindo M; Hamada K; Oda Y; Okuno T
    Hepatology; 2001 May; 33(5):1299-302. PubMed ID: 11343259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of high dose of recombinant alpha 2b interferon on long term response in chronic hepatitis C and cirrhosis: prospective randomized multicentre study.
    Ascione A; De Luca M; Canestrini C; Di Costanzo GG; Raimondo G; Longo G; Manns MP; Tillmann HL; Forte GB; Rocco P; Biceglia O; Faleo D; Vinelli F; Cela EM; Amitrano L; Addario L; Gigliotti T
    Ital J Gastroenterol Hepatol; 1998 Oct; 30(5):517-23. PubMed ID: 9836109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan.
    Huang JF; Yu ML; Lee CM; Dai CY; Hou NJ; Hsieh MY; Wang JH; Lu SN; Sheen IS; Lin SM; Chuang WL; Liaw YF
    Aliment Pharmacol Ther; 2007 May; 25(9):1029-37. PubMed ID: 17439503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 5-year prospective study of the late resolution of chronic hepatitis C after antiviral therapy.
    Annicchiarico BE; Siciliano M; Avolio AW; Grillo RL; Bombardieri G
    Aliment Pharmacol Ther; 2007 May; 25(9):1039-46. PubMed ID: 17439504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon retreatment of patients with chronic hepatitis C. A long-term follow-up.
    Spadaro A; Freni MA; Ajello A; Alessi N; Barbaro E; Resta ML; Ferraü O
    Hepatogastroenterology; 1999; 46(30):3229-33. PubMed ID: 10626191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group.
    Bernardinello E; Cavalletto L; Chemello L; Mezzocolli I; Donada C; Benvegnú L; Merkel C; Gatta A; Alberti A
    Hepatogastroenterology; 1999; 46(30):3216-22. PubMed ID: 10626189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
    Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
    Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic iron stainings in chronic hepatitis C patients with low HCV RNA levels: a predictive marker for IFN therapy.
    Akiyoshi F; Sata M; Uchimura Y; Suzuki H; Tanikawa K
    Am J Gastroenterol; 1997 Sep; 92(9):1463-6. PubMed ID: 9317063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation.
    Casanovas-Taltavull T; Baliellas C; Benasco C; Serrano TT; Casanova A; Pérez JL; Guerrero L; González MT; Andres E; Gil-Vernet S; Casais LA
    Am J Gastroenterol; 2001 Apr; 96(4):1170-7. PubMed ID: 11316166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy.
    Yu ML; Lin SM; Lee CM; Dai CY; Chang WY; Chen SC; Lee LP; Lin ZY; Hsieh MY; Wang LY; Chuang WL; Liaw YF
    Hepatology; 2006 Nov; 44(5):1086-97. PubMed ID: 17058238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiles of HCV core protein and viremia in chronic hepatitis C: possible protective role of core antigen in liver damage.
    Carabaich A; Ruvoletto M; Bernardinello E; Tono N; Cavalletto L; Chemello L; Gatta A; Pontisso P
    J Med Virol; 2005 May; 76(1):55-60. PubMed ID: 15778969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of patients with HCV infection poorly tolerant to recombinant interferon alpha.
    Cagnoni C; Pancotti D; Carrara G
    Hepatogastroenterology; 2000; 47(31):199-203. PubMed ID: 10690609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.